Pancreatic Cancer Research

ResearcherTokushima UniversityActive in the last 2 years

Tetsuji Takayama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0175-1573; OpenAlex author ID A5030298726. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment. Last author DOI 10.1007/s10147-024-02677-y↗
  2. Exosomal miR-199a-3p Secreted From Cancer-Associated Adipocytes Promotes Pancreatic Cancer Progression. Last author DOI 10.1002/cam4.70265↗
  3. Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/biomedicines11010119↗
  4. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2020.12.031↗
  5. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinom… Co-author DOI 10.1093/carcin/bgab011↗
  6. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Last author DOI 10.1111/cas.14527↗
  7. MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer. Last author DOI 10.1159/000503225↗
  8. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Last author DOI 10.1007/s00280-015-2835-3↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuyuki Okada · 5 shared papers, 2015–2025 · strength 0.78
  2. Ajay Goel · 3 shared papers, 2021–2023 · strength 0.52
  3. Masanori Takehara · 4 shared papers, 2015–2024 · strength 0.41
  4. Kazuyoshi Noda · 2 shared papers, 2020–2024 · strength 0.28
  5. Caiming Xu · 1 shared paper, 2023 · strength 0.18
  6. Cristina Fillat · 1 shared paper, 2023 · strength 0.18
  7. Silvia Pascual-Sabater · 1 shared paper, 2023 · strength 0.18
  8. Keisuke Okuno · 1 shared paper, 2023 · strength 0.18
  9. Haiyong Han · 1 shared paper, 2023 · strength 0.18
  10. Satoshi Nishiwada · 1 shared paper, 2021 · strength 0.15
  11. Hideo Baba · 1 shared paper, 2021 · strength 0.15
  12. Masayuki Sho · 1 shared paper, 2021 · strength 0.15
  13. Kensuke Yamamura · 1 shared paper, 2021 · strength 0.15
  14. Jun Okazaki · 2 shared papers, 2015–2020 · strength 0.13
  15. Tetsuya Ikemoto · 1 shared paper, 2020 · strength 0.10
  16. Mitsuo Shimada · 1 shared paper, 2020 · strength 0.10
  17. Takahiro Goji · 1 shared paper, 2015 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.